

KRYSTAL-12

METASTATIC NON-SMALL CELL
LUNG CANCER ◦ KRAS G12C

Knowledge Is Power



- Approximately 14% of metastatic NSCLC tumors test positive for the KRAS G12C mutation. If your tumor has this mutation and you have been previously treated for NSCLC with a platinum-based regimen and an immune checkpoint inhibitor, you may be eligible to participate in a clinical study of an investigational treatment.
- **Not sure if you have the KRAS G12C mutation? Testing is available.**



- **To see if the KRYSTAL-12 Study is right for you, please speak with a member of our study team.**



www.KRYSTALprogram.com

MIRATI
THERAPEUTICS